Cardiol Therapeutics (CRDL) Net Income (2020 - 2026)

Cardiol Therapeutics' Net Income history runs 6 years deep, the most recent figure standing at -$6.9 million for Q1 2026.

• Quarterly Net Income fell 21.58% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 million (down 21.58% YoY) and the FY2025 annual result came in at -$24.1 million, up 13.91% from the prior year.
• Net Income was -$6.9 million for Q1 2026 at Cardiol Therapeutics, down from -$5.7 million in the prior quarter.
• Across five years, Net Income topped out at -$5.7 million in Q1 2025 and bottomed at -$9.8 million in Q3 2022.
• A 4-year average of -$7.1 million and a median of -$6.9 million in 2026 frame the typical range for Net Income.
• Peak annual rise in Net Income reached 39.64% in 2022, while the deepest fall reached 36.24% in 2022.
• Cardiol Therapeutics' Net Income stood at -$6.4 million in 2022, then grew by 6.64% to -$6.0 million in 2024, then advanced by 4.31% to -$5.7 million in 2025, then slipped by 21.58% to -$6.9 million in 2026.
• Business Quant data shows CRDL's Net Income at -$6.9 million in Q1 2026, -$5.7 million in Q1 2025, and -$6.0 million in Q1 2024.